Patents by Inventor M. Prathap Reddy

M. Prathap Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cationic lipid cordiarimide hybrid compounds and a process for preparation thereof
    Patent number: 10266564
    Abstract: The present invention relates to the cationic lipid cordiaroimide hybrid compounds of formula I. The present invention provides a process for preparation of these compounds is also being elaborated. The compounds described provides anticancerous activity against cell lines including PC-3 (prostate cancer), HepG2 (liver cancer), MCF-7 (breast cancer) and NIH-1/3T3 (non cancer cells. The compound was also capable of inducing caspase-3 mediated apoptosis in HepG2 cells by arresting the cell cycle in the G1 phase. Furthermore, the compound exhibited DNA ligase I inhibition. The present class of cationic lipid cordiarimide hybrids is likely to find specific use in developing novel targeted therapies for liver and prostate cancers.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: April 23, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventors: Bathula Surendar Reddy, V.k.k. Durga Rao, Komal Sharma, M. Prathap Reddy, Dibyendu Banerjee, Deependra Kumar Singh
  • CATIONIC LIPID CORDIARIMIDE HYBRID COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF
    Publication number: 20170137462
    Abstract: The present invention relates to the cationic lipid cordiaroimide hybrid compounds of formula I. The present invention provides a process for preparation of these compounds is also being elaborated. The compounds described provides anticancerous activity against cell lines including PC-3 (prostate cancer), HepG2 (liver cancer), MCF-7 (breast cancer) and NIH-1/3T3 (non cancer cells. The compound was also capable of inducing caspase-3 mediated apoptosis in HepG2 cells by arresting the cell cycle in the G1 phase. Furthermore, the compound exhibited DNA ligase I inhibition. The present class of cationic lipid cordiarimide hybrids is likely to find specific use in developing novel targeted therapies for liver and prostate cancers.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 18, 2017
    Inventors: Bathula Surendar Reddy, V.k.k. Durga Rao, Komal Sharma, M. Prathap Reddy, Dibyendu Banerjee, Deependra Kumar Singh